

PROTECT PATIENTS & MEDICAL INNOVATION IN NEW JERSEY



ICER could endanger Patient access to the innovative medicines they need and harm New Jersey's thriving life sciences industry.

The Impact of New Jersey's Life Sciences Industry

New Jersey's life sciences ecosystem drives prosperity and better health outcomes in New Jersey and beyond.

Nearly 5,600 life sciences establishments

350,000+ high-quality jobs

\$120.9 billion annual economic impact

What incentive would life sciences companies have to innovate if the drugs they produce can't reach the Patients who need them? ICER could bring innovation to a halt.

Join BioNJ in our efforts to advocate for policies and solutions that help Patients access the medicines they need and promote a thriving life sciences industry in New Jersey and beyond.

What is ICER?

The Institute for Clinical and Economic Review (ICER) is a Boston-based research group that uses a controversial method to determine the value of drugs. ICER uses the "Quality Adjusted Life Years" (QALY) methodology to determine treatment value, which is based on an arbitrary evaluation of the value of one year of perfect health.

- ✓ ICER Ignores Individual Patient Preferences
- ✓ ICER's Approach to Value Assessment May Be Discriminatory

What Does ICER Mean for Patients?

The ICER value assessment model threatens to limit Patient access to life-saving treatments. ICER's approach to drug value assessment may also be discriminatory, as it places a lower value on the lives of the disabled, the elderly, and Patients with rare or chronic disease. When Patients can't access the treatments they need to manage their health, it can lead to complications, increased doctor visits, trips to the ER, and even death.

ICER Could Harm Medical Innovation in New Jersey and Beyond.

In an effort to control the cost of care, health plans and policymakers are actively exploring the use of drug value assessments – such as those ICER uses – to determine whether or not certain treatments should be covered. But most drug value assessment frameworks are subjective, based on a one-size-fits-all equation, and could limit Patient access to innovative treatments.

[BioNJ.org/Protect-Medical-Innovation](https://www.bionj.org/protect-medical-innovation)